Biomea Fusion Investor Relations Material
Latest events
FDA Announcement
Biomea Fusion
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Biomea Fusion Inc
Access all reports
Biomea Fusion Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery and development of covalent small molecule drugs. These drugs are designed to treat patients with genetically defined cancers and metabolic diseases. The company’s approach leverages covalent bonding, where a small molecule forms a permanent bond with its target protein, which may offer advantages like greater target selectivity and a more durable therapeutic response. The company is headquartered in Redwood City, California, and its shares are listed on the NASDAQ.
Latest articles
Deere & Company: Shaping the Future of Agriculture Since 1837
Detailing the history of agriculture and Deere & Company, all the way from 1837 to the present day.
25 Oct 2024
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Ticker symbol
BMEA
Country
🇺🇸 United States